Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000493149 | SCV000581856 | likely pathogenic | not provided | 2015-07-21 | criteria provided, single submitter | clinical testing | The E502V variant in the PKHD1 gene has not been published as a pathogenic variant, nor has it been reported as a benign polymorphism to our knowledge. The E502V variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The E502V variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position where amino acids with similar properties to Glutamate are tolerated across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. Missense variants in nearby residues (R496P, Q504H) have been reported in the Human Gene Mutation Database in association with polycystic kidney disease (Stenson et al., 2014), supporting the functional importance of this region of the protein. The E502V variant is a strong candidate for a disease-causing variant, however the possibility it may be a rare benign variant cannot be excluded |